Lexeo Therapeutics, Inc.
corporate_fare Company Profile
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for LXEO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for LXEO spans 10-Q, 8-K.
Recent high-impact activity:
- Lexeo 10-Q: $219.1M Cash Funds Operations Into 2028; Q3 Net Loss $38.3M
- Lexeo's LX2020 Cuts NSVT 80%; FDA Open to NSVT Endpoint for Accelerated Approval
- LX2020 Cuts Arrhythmia Burden 80% in High-Dose Cohorts; FDA Open to NSVT Endpoint
- LX2006 Shows Sustained Neurologic Benefit Versus Natural-History Control
- Lexeo Acquires Mantle Therapeutics for $8.3M Upfront, Adds Four FA Programs and Three CNS Collaborations
Financial Snapshot
Short Interest & Short Volume
12.73 days to coverFINRA reported short interest of 17,037,063 shares in LXEO as of the October 30, 2026 settlement, a 2.9% decrease from the prior period — about 12.7 days to cover at its recent average daily volume. On November 20, 2026, 48.6% of LXEO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for LXEO, detected from its recent SEC filings.
New $300M Universal Shelf Filed · $116.6M Carried Forward, $183.4M New
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →